<https://rdf.molmedb.upol.cz/reference/ref4087> <http://purl.org/ontology/bibo/pmid> "29779975"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://identifiers.org/molmedb/MM493754>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2018.05.014"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Lu T, Schubert C, Cummings MD, Bignan G, Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, Alexander R, Grasberger B, De Breucker S, Esser N, Fraiponts E, Gilissen R, Janssens B, Peeters D, Van Nuffel L, Vermeulen P, Bischoff J, Meerpoel L.: Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy. Bioorg Med Chem Lett, Volume 28 (12), 2018"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1030841> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4087> .